Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease

被引：4
|
作者：
Massoud, Fadi [1 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
来源：
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES | 2013年 / 40卷 / 05期
关键词：
DEMENTIA; DISCONTINUATION; THERAPY;
D O I：
10.1017/S0317167100014815
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：623 / 624
页数：2
相关论文
共 50 条
  • [1] Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease
    Le Couteur, David G.
    Robinson, Maxine
    Leverton, Ann
    Creasey, Helen
    Waite, Louise
    Atkins, Kerry
    McLachlan, Andrew J.
    AUSTRALASIAN JOURNAL ON AGEING, 2012, 31 (03) : 164 - 169
  • [2] Persistence with cholinesterase inhibitor therapy in a population based cohort of patients with Alzheimer's disease
    Amuah, Joseph E.
    Hogan, David B.
    Eliasziw, Misha
    Supina, Alison
    Beck, Patricia
    Downey, Winanne
    Maxwell, Colleen J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (07) : 670 - 679
  • [3] Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
    Motter, Jeffrey N.
    Liu, Xinhua
    Qian, Min
    Cohen, Hannah R.
    Devanand, Davangere P.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2021, 13 (01)
  • [4] Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease
    Mezeiova, Eva
    Prchal, Lukas
    Hrabinova, Martina
    Muckova, Lubica
    Pulkrabkova, Lenka
    Soukup, Ondrej
    Misiachna, Anna
    Janousek, Jiri
    Fibigar, Jakub
    Kucera, Tomas
    Horak, Martin
    Makhaeva, Galina F.
    Korabecny, Jan
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [5] Increase in Platelet Immunoglobulin in Alzheimer's Disease is Normalised Following Cholinesterase Inhibitor Treatment: Preliminary Results
    Mukaetova-Ladinska, Elizabeta B.
    Abdel-All, Zeinab
    Andrade, Joana
    McNally, Richard J. Q.
    James, Peter W.
    Kalaria, Raj N.
    O'Brien, John T.
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 32 (02) : 431 - 436
  • [6] Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors
    Versijpt, Jan
    ACTA NEUROLOGICA BELGICA, 2012, 112 (02) : 141 - 145
  • [7] Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
    Small, Gary
    Bullock, Roger
    ALZHEIMERS & DEMENTIA, 2011, 7 (02) : 177 - 184
  • [8] Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease
    Miettinen, Pekka S.
    Jauhiainen, Anne M.
    Tarkka, Ina M.
    Pihlajamaki, Maija
    Grohn, Heidi
    Niskanen, Eini
    Hanninen, Tuomo
    Vanninen, Ritva
    Soininen, Hilkka
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 40 (5-6) : 243 - 255
  • [9] Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan
    Ku, Li-Jung Elizabeth
    Li, Chung-Yi
    Sun, Yu
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2018, 33 (02): : 86 - 92
  • [10] Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease
    Patterson, C. E.
    Todd, S. A.
    Passmore, A. P.
    PHARMACOGENOMICS JOURNAL, 2011, 11 (06): : 444 - 450
12345